Search Results - "Ribavirin/pharmacology/ therapeutic use"

Viral hepatitis C

Authors: Yuen, MF Lung Lai, C Poynard, T et al.

Source: The Lancet. 362:2095-2100

Subject Terms: Adult, Liver Cirrhosis, Interferon-alpha - pharmacology - therapeutic use, Genotype, Ribavirin - pharmacology - therapeutic use, Enzyme-Linked Immunosorbent Assay, HIV Infections, Comorbidity, Hepacivirus, Interferon alpha-2, Severity of Illness Index, Antiviral Agents, Hepatitis C, Chronic - diagnosis - drug therapy - epidemiology, Polyethylene Glycols, 03 medical and health sciences, 0302 clinical medicine, Viral - analysis - genetics - immunology, Ribavirin, Humans, Hepacivirus - drug effects - genetics - isolation & purification, Serotyping, HIV Infections - drug therapy - epidemiology, RNA, Viral - analysis - genetics - immunology, Polyethylene Glycols - pharmacology - therapeutic use, Interferon-alpha, Hepatitis C, Chronic, Antiviral Agents - pharmacology - therapeutic use, Hepatitis C, Recombinant Proteins, 3. Good health, Hepatitis C - diagnosis - drug therapy - epidemiology, Liver Cirrhosis - diagnosis - pathology, Chronic - diagnosis - drug therapy - epidemiology, Interferons - pharmacology - therapeutic use, Disease Progression, RNA, RNA, Viral, Interferons

Access URL: https://pubmed.ncbi.nlm.nih.gov/14697814
https://www.sciencedirect.com/science/article/pii/S0140673603151094
https://www.ncbi.nlm.nih.gov/pubmed/14697814
https://pubmed.ncbi.nlm.nih.gov/14697814/
https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)15109-4.pdf
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)15109-4.pdf
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)15109-4/fulltext
http://hdl.handle.net/10722/76969

Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Genotype 6: A Comparison with Genotype 1

Authors: Chan, AOO Wong, BCY Lai, CL et al.

Source: The Journal of Infectious Diseases. 187:1071-1074

Subject Terms: Adult, Male, 0301 basic medicine, Genes, Viral, Genotype, Antiviral agents - therapeutic use, Ribavirin - pharmacology - therapeutic use, Hepacivirus, Interferon alpha-2, Hepatitis c, Antiviral Agents, Interferon alfa-2b - pharmacology - therapeutic use, 03 medical and health sciences, Ribavirin, Humans, Aged, Aged, 80 and over, Interferon-alpha, Hepatitis C, Chronic, Middle Aged, Recombinant Proteins, 3. Good health, chronic - drug therapy - virology, Drug Therapy, Combination, Female, Hepacivirus - drug effects - genetics, Hepatitis c, chronic - drug therapy - virology

File Description: 85405 bytes; 3035 bytes; 2319 bytes; application/pdf; text/plain

Access URL: https://academic.oup.com/jid/article-pdf/187/7/1071/2393427/187-7-1071.pdf
https://pubmed.ncbi.nlm.nih.gov/12660921
http://hub.hku.hk/bitstream/10722/42154/1/80554.pdf
https://core.ac.uk/display/37881522
https://paperity.org/p/58709919/interferon-and-ribavirin-therapy-for-chronic-hepatitis-c-virus-genotype-6-a-comparison
http://hub.hku.hk/handle/10722/42154
https://www.ncbi.nlm.nih.gov/pubmed/12660921
http://hdl.handle.net/10722/42154

Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment

Authors: Elefsiniotis, I. S. Petrocheilou, A. Scarmeas, N. et al.

Source: Journal of Clinical Virology. 37:329-331

Subject Terms: Adult, Calcitonin, Male, 0301 basic medicine, Calcitonin Gene-Related Peptide, Interferon alpha-2, Antiviral Agents, Polyethylene Glycols, 03 medical and health sciences, Ribavirin, Humans, Protein Precursors, Antiviral Agents/therapeutic use, Interferon-alpha, Hepatitis C, Chronic, Middle Aged, Ribavirin/*pharmacology/therapeutic use, Recombinant Proteins, 3. Good health, Protein Precursors/*blood, Hepatitis C, Chronic/drug therapy/*metabolism, Drug Therapy, Combination, Female, Polyethylene Glycols/*pharmacology/therapeutic use, Interferon-alpha/*pharmacology/therapeutic use, Calcitonin/*blood

Access URL: https://pubmed.ncbi.nlm.nih.gov/16996792
https://pubmed.ncbi.nlm.nih.gov/16996792/
http://www.sciencedirect.com/science/article/pii/S138665320600309X
https://www.ncbi.nlm.nih.gov/pubmed/16996792
https://www.sciencedirect.com/science/article/pii/S138665320600309X
http://olympias.lib.uoi.gr/jspui/handle/123456789/18347

Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6

Authors: Lukasiewicz, Esther Hellstrand, Kristoffer Westin, Johan et al.

Source: Hepatology. 45(1):258-9

Subject Terms: Medical and Health Sciences, Medicin och hälsovetenskap, Antiviral Agents/pharmacology/ therapeutic use, Clinical Trials, Drug Therapy, Combination, Europe, Follow-Up Studies, Genotype, Hepacivirus/drug effects/ genetics, Hepatitis C/blood/ drug therapy/genetics, Humans, Interferon Alfa-2a/pharmacology/ therapeutic use, Multicenter Studies, Polyethylene Glycols/pharmacology/ therapeutic use, Predictive Value of Tests, RNA, Viral/ blood, Ribavirin/pharmacology/ therapeutic use, Treatment Outcome, Viral Load

Access URL: https://gup.ub.gu.se/publication/55067